Predictive performance of the competing risk model in screening for preeclampsia by Wright, David et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1016/j.ajog.2018.11.1087
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Wright, D., Tan, M. Y., O’Gorman, N., Poon, L. C., Syngelaki, A., Wright, A., & Nicolaides, K. H. (2018).
Predictive performance of the competing risk model in screening for preeclampsia. American Journal of
Obstetrics and Gynecology. https://doi.org/10.1016/j.ajog.2018.11.1087
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 10. Jul. 2020
Accepted Manuscript
Predictive performance of the competing risk model in screening for preeclampsia
David Wright, Ph.D., Min Yi Tan, M.D., Neil O’Gorman, M.D., Liona C. Poon, M.D.,
Argyro Syngelaki, Ph.D., Alan Wright, Ph.D., Kypros H. Nicolaides, M.D.
PII: S0002-9378(18)32112-4
DOI: https://doi.org/10.1016/j.ajog.2018.11.1087
Reference: YMOB 12435
To appear in: American Journal of Obstetrics and Gynecology
Received Date: 11 September 2018
Revised Date: 28 October 2018
Accepted Date: 8 November 2018
Please cite this article as: Wright D, Tan MY, O’Gorman N, Poon LC, Syngelaki A, Wright A, Nicolaides
KH, Predictive performance of the competing risk model in screening for preeclampsia, American
Journal of Obstetrics and Gynecology (2018), doi: https://doi.org/10.1016/j.ajog.2018.11.1087.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 1
Predictive performance of the competing risk model in screening for 
preeclampsia 
 
David WRIGHT, Ph.D.,1 Min Yi TAN, M.D.,2 Neil O’GORMAN M.D.,1 Liona C. POON, 
M.D.,2  Argyro SYNGELAKI, Ph.D.,2 Alan WRIGHT, Ph.D.1 Kypros H. NICOLAIDES, 
M.D.1 
 
1. Institute of Health Research, University of Exeter, Exeter, UK. 
2. Harris Birthright Research Centre for Fetal Medicine, King’s College, London, UK. 
 
Correspondence:  
Professor KH Nicolaides, Harris Birthright Research Centre for Fetal Medicine, Fetal 
Medicine Research Institute, King's College Hospital, Denmark Hill, London SE5 8BB, 
UK.   Tel: 00 44 2032998256, email: kypros@fetalmedicine.com 
 
Conflict of interest: None 
 
Acknowledgement: The study was supported by a grant from the Fetal Medicine 
Foundation (UK Charity No: 1037116). This body had no involvement in the study 
design; in the collection, analysis and interpretation of data; in the writing of the 
report; and in the decision to submit the article for publication. 
 
Abstract word count: 619, Main text word count: 3514 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 2
Condensation 
Results from two validation datasets are consistent good with those of the training set 
used for development of the competing risk model of screening for preeclampsia.  
 
Short version of article title 
Competing risks model in screening for preeclampsia  
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ABSTRACT 
Background 
The established method of screening for preeclampsia (PE) is to identify risk factors 
from maternal demographic characteristics and medical history; in the presence of 
such factors the patient is classified as high-risk and in their absence as low-risk. 
However, the performance of such approach is poor. We developed a competing risks 
model which allows combination of maternal factors (age, weight, height, race, parity, 
personal and family history of PE, chronic hypertension, diabetes mellitus, systemic 
lupus erythematosus or antiphospholipid syndrome, method of conception and 
interpregnancy interval), with biomarkers to estimate the individual patient-specific 
risks of PE requiring delivery before any specified gestation. The performance of this 
approach is by far superior to that of the risk scoring systems. 
Objective: To examine the predictive performance of the competing risks model in 
screening for PE by a combination of maternal factors, mean arterial pressure (MAP), 
uterine artery pulsatility index (PI), and serum placental growth factor (PLGF), 
referred to as the triple test, in a training dataset for development of the model and 
two validation studies. 
Study design: The data for this study were derived from three previously reported 
prospective non-intervention multicenter screening studies for PE in singleton 
pregnancies at 11+0 – 13+6 weeks’ gestation. In all three studies, there was recording 
of maternal factors and biomarkers and ascertainment of outcome by appropriately 
trained personnel. The first study of 35,948 women, which was carried out between 
February 2010 and July 2014, was used to develop the competing risks model for 
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prediction of PE and is therefore considered to be the training set. The two validation 
studies comprised of 8,775 and 16,451 women, respectively and they were carried 
out between February and September 2015 and between April and December 2016, 
respectively. Patient-specific risks of delivery with PE at <34, <37 and <41+3 weeks’ 
gestation were calculated using the competing risks model and the performance of 
screening for PE by maternal factors alone and the triple test in each of the three 
datasets was assessed. We examined the predictive performance of the model by 
first, the ability of the model to discriminate between the PE and no PE groups using 
the area under the receiver operating characteristic (AUROC) curve and the detection 
rate (DR) at fixed screen positive rate (SPR) of 10%, and second, calibration by 
measurements of calibration slope and calibration-in-the-large. 
Results: The DR at SPR of 10% of early-PE, preterm-PE and all-PE was about 90%, 
75% and 50%, respectively and the results were consistent between the training and 
two validation datasets. The AUROC curve was >0.95, >0.90 and >0.80, respectively, 
demonstrating a very high discrimination between affected and unaffected 
pregnancies. Similarly, the calibration slopes were very close to 1.0 demonstrating a 
good agreement between the predicted risks and observed incidence of PE. In the 
prediction of early-PE and preterm-PE the observed incidence in the training set and 
one of the validation datasets was consistent with the predicted one. In the other 
validation dataset, which was specifically designed for evaluation of the model, the 
incidence was higher than predicted presumably because of better ascertainment of 
outcome. The incidence of all-PE was lower than predicted in all three datasets 
because at term many pregnancies deliver for reasons other than PE and therefore 
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pregnancies considered to be at high-risk for PE that deliver for other reasons before 
they develop PE can be wrongly considered to be false positives. 
Conclusions: The competing risks model provides an effective and reproducible 
method for first-trimester prediction of early-PE and preterm-PE, as long as the 
various components of screening are carried out by appropriately trained and audited 
practitioners. Early prediction of preterm-PE is beneficial because treatment of the 
high-risk group with aspirin is highly effective in the prevention of the disease. 
 
Key words: First trimester screening, Preeclampsia, Competing risks model, Survival 
model, Performance of screening, Discrimination, Calibration, Aspirin, ASPRE trial, 
Uterine artery Doppler, Mean arterial blood pressure, Placental growth factor. 
 
AJOG at a Glance 
 
A. To assess the predictive performance of the competing risks model for 
preeclampsia using the first trimester triple test that combines maternal factors, 
mean arterial pressure, uterine artery pulsatility index, and serum placental 
growth factor. 
 
B. Results from two prospective multi-center validation data sets show that, with 
appropriately trained staff and quality control of measurement, preeclampsia, 
especially that leading to early delivery, can be predicted effectively using the 
triple test. These results are consistent with those obtained from the training data 
set. 
 
C. The competing risks model provides an effective and reproducible method for 
first-trimester prediction of preeclampsia.   
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Introduction 
 
The established method of screening for PE is to identify risk factors from maternal 
demographic characteristics and medical history; in the presence of such factors the 
patient is classified as high-risk and in their absence as low-risk.1,2 The performance 
of this approach is poor 3-5 and, though it is simple, it does not quantify individual 
patient specific risks.  An alternative way of screening is to use logistic regression 
models fitted to maternal characteristics and medical history alone or in combination 
with biomarkers to predict early, late or all PE.6-10 Such models are useful in 
quantifying the individual patient specific risk for PE, rather than just classifying 
women into high- and low-risk groups. However, they do not allow the flexibility of 
selecting different gestational age cut-offs for categorizing the severity of PE, they do 
not take into account the fact that the deviation in biomarker levels from normal 
depends on the severity of the disease and they cannot be easily expanded to include 
additional biomarkers measured at different stages in pregnancy. 
 
We have developed a competing risks approach that allows combination of maternal 
factors with biomarkers to estimate the individual patient-specific risks of PE requiring 
delivery before any specified gestation.11,12 This is based on a survival-time model for 
the gestational age at delivery with PE and it is assumed that if the pregnancy was to 
continue indefinitely all women would develop PE and whether they do so or not 
before a specified gestational age depends on competition between delivery before or 
after development of PE. Based on model fit and ease of interpretation, a Gaussian 
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model for gestational age at delivery was chosen. The effects of variables from 
maternal factors and biomarkers is to modify the distribution of gestational age at 
delivery with PE so that in pregnancies at low risk for PE the gestational age 
distribution is shifted to the right with the implication that in most pregnancies delivery 
will actually occur before development of PE. In high-risk pregnancies the distribution 
is shifted to the left and the smaller the mean gestational age the higher is the risk for 
PE. In one previous study of 120,492 singleton pregnancies undergoing screening at 
11-13 weeks’ gestation we reported the development of the competing risks model 
based on maternal characteristics and medical history, including age, weight, height, 
race, parity, personal and family history of PE, chronic hypertension, diabetes 
mellitus, systemic lupus erythematosus or antiphospholipid syndrome, method of 
conception and interpregnancy interval.3 In another study of 35,948 singleton 
pregnancies we reported effective screening for preterm-PE, with delivery at <37 
weeks’ gestation, by a combination of maternal factors with mean arterial pressure 
(MAP), uterine artery pulsatility index (PI), and serum placental growth factor 
(PLGF).13 A limitation of the study was that the performance of screening by a model 
derived and tested using the same dataset is overestimated. We used cross 
validation to reduce this effect, but suggested the necessity for external validation on 
independent data from different sources.  
 
The objective of this study is to examine the predictive performance of the competing 
risks model in screening for PE with delivery <34 weeks (early-PE), <37 weeks 
(preterm-PE) and delivery at any gestation (all-PE) by maternal factors alone and a 
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combination of maternal factors, MAP, UtA-PI and PLGF (triple test) in the training 
dataset13 for development of the model and two validation studies. 
 
Methods 
Study populations 
The data for this study were derived from three previously reported prospective non-
intervention screening studies at 11+0 – 13+6 weeks’ gestation with a combined total of 
61,174 singleton pregnancies, including 1,770 (2.9%) that developed PE.4,13,14  
 
The first study comprised of 35,948 women attending for their routine first hospital 
visit in pregnancy at King’s College Hospital and Medway Maritime Hospital, UK, 
between February 2010 and July 2014.13 This dataset was used to develop the 
competing risks model for prediction of PE and is therefore considered to be the 
training set. The second study, referred to as SQS (screening quality study), 
comprised of 8,775 singleton pregnancies undergoing first-trimester screening for PE, 
using the competing risks model developed in the first study,13  in 12 maternity 
hospitals in England, Spain, Belgium, Italy and Greece, between February and 
September 2015.14 This study was carried out before ASPRE (Combined Multimarker 
Screening and Randomized Patient Treatment with Aspirin for Evidence-Based 
Preeclampsia Prevention) trial 15 and was primarily designed to examine the feasibility 
of multicenter screening and establish methods for quality assurance of the 
biomarkers and the results from screening were not made available to the patients or 
their obstetricians. The third study, referred to as SPREE, was a multicenter cohort 
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study in 16,451 women carried out in seven National Health Service maternity 
hospitals in England, between April and December 2016.4 This study was specifically 
designed to examine the performance of screening by the algorithm established in the 
first study13 in comparison with that of the method advocated by NICE;1 the results 
from screening by the competing risks model were not made available to the patients 
or their obstetricians. 
 
In all three studies, women with singleton pregnancies in the participating hospitals 
had a routine examination at 11+0 - 13+6 weeks’ gestation. This visit included first, 
recording of maternal characteristics and medical history,3 second, measurement of 
the left and right UtA-PI by transabdominal color Doppler ultrasound and calculation 
of the mean PI,16 third, measurement of MAP by validated automated devices and 
standardized protocol,17 and fourth, measurement of serum concentration of PLGF 
(DELFIA Xpress system, PerkinElmer Life and Analytical Sciences, Waltham, USA or 
BRAHMS KRYPTOR analyzer, Thermo Fisher Scientific, Hennigsdorf, Germany). 
The measurements of MAP were carried out by healthcare assistants or 
sonographers who had received specific training for this purpose and measurements 
of UtA-PI were performed by doctors or sonographers who had obtained the Fetal 
Medicine Foundation Certificate of Competence in Doppler ultrasound. In both 
validation studies quality control was applied on a monthly basis to achieve 
consistency of measurement of biomarkers across different hospitals throughout the 
duration of the study. The distribution of measurements of MAP and UtA-PI  were 
reported to the coordinator who provided feedback and if necessary retraining of the 
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personnel with large deviations from the expected values. Similarly the laboratories 
were provided with diagnostics for PLGF measurements so that appropriate 
corrective actions could be undertaken. Gestational age was determined from the 
fetal crown-rump length.18 The women gave written informed consent to participate in 
the studies, which were approved by the relevant research ethics committee in each 
participating hospital. 
 
The inclusion criteria were singleton pregnancy undergoing first-trimester combined 
screening for PE and subsequently delivering a morphologically normal live birth or 
stillbirth at >24 weeks’ gestation. We excluded pregnancies with aneuploidies and 
major fetal abnormalities and those ending in termination, miscarriage or fetal death 
before 24 weeks.  
 
Outcome measures were early-PE, preterm-PE and all-PE. Data on pregnancy 
outcome were collected from the hospital maternity records or the general medical 
practitioners of the women. The obstetric records of all women with pre-existing or 
pregnancy associated hypertension were examined to determine if the condition was 
PE, as defined by the International Society for the Study of Hypertension in 
Pregnancy.19 This includes the finding of hypertension (systolic blood pressure of 
>140 mm Hg or diastolic blood pressure of >90 mmHg on at least two occasions four 
hours apart developing after 20 weeks’ gestation in previously normotensive women) 
and proteinuria (≥300 mg/24h or protein to creatinine ratio >30 mg/mmol or >2 + on 
dipstick testing), 
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Statistical analysis 
Patient-specific risks of delivery with PE at <34, <37 and <41+3 weeks’ gestation were 
calculated using the competing risks model to combine the prior distribution of the 
gestational age at delivery with PE, obtained from maternal characteristics and 
medical history, with multiple of the median (MoM) values of MAP, UtA-PI and 
PLGF.3,13 The performance of screening for early-PE, preterm-PE and all-PE by the 
triple test in each of the three datasets was assessed.  
 
We examined the predictive performance of the model by first, the ability of the model 
to discriminate between the PE and no PE groups and second, calibration, which 
assesses agreement between predicted risks and outcomes (for a well calibrated 
model, amongst those women with a risk of 1 in n the incidence should be 1 in n). 
Discrimination was assessed by the area under the receiver operating characteristic 
(AUROC) curve (this indicates perfect discrimination if the value is 1 and no 
discrimination beyond chance if the value is 0.5) and the DR at fixed SPR of 10%. 
Calibration was assessed visually through a series of figures showing the observed 
incidence against that predicted from risk for PE <32, <34, <37 and <41+3 weeks’ 
gestation by maternal factors and the triple test. The plots were produced by grouping 
the data into bins according to risk. The observed incidence in each group was then 
plotted against the incidence predicted by the model (i.e. the mean risks within each 
group). Quantitative assessment of calibration was by recording of measurements of 
calibration in-the-large and calibration slope. Calibration-in-the-large is a measure of 
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whether generally the risks are too high or too low. This is quantified by the estimated 
intercept from a logistic regression of incidence on the logit of risk with the slope fixed 
at 1. The intercept is a measure of the deviation of the observed incidence from the 
predicted. For perfectly calibrated risks, the intercept should be zero. If there is a 
general tendency for underestimation, so that the observed incidence is larger than 
that predicted, the intercept will be positive. Conversely, for overestimation, the 
intercept will be negative. The calibration slope assesses the calibration across the 
range of risks and is the slope of the regression line of the logistic regression of 
incidence on the logit of risk. If the risk is well calibrated, then the slope should be 1.0. 
A slope less than 1 means that the relationship between risk and incidence is flatter 
than it should be. A calibration slope greater than 1 means the relationship is steeper 
than it should be.   
 
The risks produced from our competing risks model are for delivery with PE before a 
specific gestation assuming no other cause for delivery. Because other cause 
deliveries are effectively censored observations, the actual incidence of PE would be 
expected to be lower than predicted. For early gestations, when there are few other 
cause deliveries, the effects would be small.  At later gestations, with many other 
cause deliveries, the effect of censoring may be substantial. Consequently, we 
applied survival analysis (Kaplan Meier) to estimate incidence of delivery with PE 
treating deliveries from other causes as censored observations.  
 
The statistical software package R was used for data analyses.20 The package pROC 
was used for the receiver operating characteristic (ROC) curve analysis and the 
package survival was used for survival analysis.21-23 
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Results 
Maternal and pregnancy characteristics in the training set, SQS and SPREE 
populations are provided and compared in Table 1.  
 
Performance of screening for early-PE, preterm-PE and all-PE is given in Table 2. 
Receiver operating characteristics curves for the performance of screening for early-
PE, preterm-PE and all-PE in the three datasets and their combination by the triple 
test are shown in Figures 1, S1 and S2. Calibration plots of the predictive 
performance of the competing risks model for early-PE, preterm-PE and all-PE using 
the triple test in the tree datasets are shown in Figures 2, S3 and S4.  
 
The AUROC curve and DR at SPR of 10% of early-PE, preterm-PE and all-PE in the 
two testing datasets were very similar to that in the training set. In the prediction of 
early-PE, preterm-PE and all-PE by the triple test the AUROC curve was >0.95, >0.90 
and >0.80, respectively, demonstrating a very high discrimination between affected 
and unaffected pregnancies. Similarly, the calibration slopes were very close to 1.0 
demonstrating a good agreement between the predicted risks and observed 
incidence of PE. 
 
In the prediction of early-PE and preterm-PE the observed incidence in the training 
and SQS datasets was consistent with the predicted one, but for SPREE the 
incidence was higher than predicted; this is likely to be due to better ascertainment of 
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outcome in SPREE. The incidence of all-PE was lower than predicted in all three 
datasets (Figure S3). After adjustment for the effect of censoring due to births from 
causes other than PE, the incidence was consistent with the predicted one (Figure 
S6). 
 
Discussion 
Main findings of the study 
This study on the predictive performance of the competing risks model for PE 
demonstrate that the results from two validation datasets, derived from prospectively 
collected data from multicenter studies, are consistent with those of the training set 
used for development of the model.  
 
The triple test provided very high discrimination between affected and unaffected 
pregnancies for early-PE and preterm-PE in each of the three datasets with values for 
the AUROC curve of >0.95, and >0.90, respectively, and DR at 10% SPR of about 
90%, and 75%, respectively. The performance of screening at 11-13 weeks for term-
PE is poor 13 and since about 70% of all cases of PE occur at term the AUROC curve 
for all-PE and the DR at 10% SPR were about 0.8 and 50%, respectively. There are 
two main reasons for poor discrimination for term-PE from screening at 11-13 weeks. 
First, in pregnancies with PE the deviation from normal in MAP, UtA-PI and PLGF 
MoM decreases with increasing gestational age and especially for UtA-PI there is little 
discrimination between term-PE and unaffected pregnancies.13 Second, at term many 
pregnancies deliver for reasons other than PE. Therefore, pregnancies considered to 
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be at high-risk for PE that deliver for other reasons are counted as false positives 
even though many would have developed PE if the pregnancy had continued. More 
effective screening for term-PE by the competing risks model can be provided at 35-
37 weeks’ gestation using a combination of maternal factors, MAP, PLGF and serum 
soluble fms-like tyrosine kinase-1 (sFLT-1).24,25   
 
Calibration refers to how well the predictions from the model agree with the observed 
outcomes. Deviations between the predicted and observed outcome do not only 
reflect on the accuracy of a given model but could also be the consequence of 
differences between the studies used for development of the model and those used 
for validation in terms of first, methodology and accuracy of recording maternal 
characteristics and medical history and the measurement of biomarkers and second, 
definition and ascertainment of the outcome measure. In all three datasets there was 
prospective collection of data on maternal factors and biomarkers using a 
standardized protocol, the same definition of PE was used and the approach to 
ascertainment of outcome was similar. The results of the study demonstrate that in 
both the training and validation datasets calibration of risks for PE were generally 
good with the calibration slope very close to 1.0. 
 
In SPREE there was a tendency for the risks to underestimate the incidence of early-
PE and preterm-PE. A possible explanation for this finding is that in the training set 
there was general screening for many pregnancy complications, the data were 
collected over many years and many doctors were involved in the ascertainment of 
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outcome. In contrast, SQS and SPREE were specifically designed for prediction of 
PE, recruitment was completed within a few months and only one doctor was overall 
responsible for ascertainment of outcome. Indeed ascertainment is SPREE is likely to 
have been higher than in SQS because the latter focused more on quality assurance 
of biomarkers rather than performance of screening. 
 
In all three datasets the observed incidence of all-PE was lower than the predicted 
one. The likely explanation for this finding is the same as for the poorer performance 
of the competing risks model for term-PE because many pregnancies with estimated 
high risk for PE would deliver earlier than the expected event for reasons other than 
PE. After adjustment for the effect of censoring due to births from causes other than 
PE, the observed incidence in the training set and SQS was closer to the predicted 
one, but in the case of SPREE, the observed incidence became higher than the 
predicted one; this finding could be a reflection of the higher ascertainment of cases 
of PE in SPREE. 
 
Strengths and limitations 
The strengths of this study include: first, use of a large dataset of prospectively 
collected data on maternal factors and biomarkers to develop the model, second, 
prospective evaluation of  discrimination and calibration of the prespecified model in 
two independent multicenter studies 4,12 which were overseen by an independent 
clinical trials unit, and third, assessment of calibration allowing for the effect of 
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censoring due to births from causes other than PE. The combined data from the 
studies is now being used to refine the competing risk model.   
 
The results of the study have confirmed the accuracy of the competing risks model. 
However, application of the model in clinical practice necessitates the appropriate 
infrastructure for accurate recording of maternal characteristics and medical history, 
appropriate training of personnel undertaking the measurement of biomarkers and 
regular audit of their results, standardization of biomarkers that may vary in different 
populations and with different assays, use of the same outcome measures and good 
ascertainment for such outcome. 
 
Results of previous studies 
A previous study examined our competing risks model in 541 nulliparous women at 
11-13 weeks’ gestation and reported that the DR of preterm-PE and all-PE, at false 
positive rate (FPR) of 10%, was 80% and 40%, respectively.26 The number of cases 
examined is very small but the results are consistent with our findings. 
 
A prospective study in 3066 women evaluated a previously published first-trimester 
algorithm for prediction of early-PE that was derived by logistic regression using 
maternal factors and biomarkers and reported that the DR, at 10% FPR, of early-PE 
was 92%, which was similar to the 95% reported in the original model.27 Another 
prospective study evaluated previously published first-trimester algorithms for 
prediction of PE that were derived by logistic regression using maternal factors and 
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biomarkers.28 The validation dataset consisted of between 871 and 2962 women, 
depending on the variables required in the published algorithms. The DR, at FPR of 
10%, in six algorithms for early-PE varied from 29 to 80% and in two algorithms for 
late-PE (≥34 weeks) it was 18% and 53%. 
 
Implications for clinical practice 
NICE and ACOG recommend screening for PE by maternal factors and treatment of 
the screen positive group with aspirin at a daily dose of 75 mg and 81 mg, 
respectively.1,2 However, recent evidence suggests such approach to prediction and 
prevention of PE is likely to be ineffective, because the performance of the screening 
method is poor and the recommended dose of aspirin is inadequate. 
 
As demonstrated by this study, the competing risks model using the triple test can 
predict about 90% of early-PE and 75% of preterm-PE, at SPR of 10%; at the same 
SPR the DR achieved by the methods recommended by NICE and ACOG is half as 
much.4 Treatment of the group identified by the competing risks model as being at 
high-risk for preterm-PE with aspirin (150 mg/day from 11-14 weeks’ gestation to 36 
weeks) reduces the rate of preterm-PE by about 60%, early-PE by about 80% and 
very early-PE by about 90%, but there is little evidence of a reduction in incidence of 
PE with delivery at term.15 Screening and prevention of PE is also associated with 
reduction in the length of stay in the neonatal intensive care unit by about 70%, 
because about 85% of such length of stay is due to births at <32 weeks which are 
substantially reduced.29 A secondary analysis of the ASPRE trial demonstrated that 
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the beneficial effect of aspirin depends on adherence and the reduction in incidence 
of preterm-PE may be about 75% in those with adherence of >90% and only 40% in 
those with adherence of <90%.30 A subgroup analysis of the ASPRE trial 
demonstrated that there was no evidence of heterogeneity in the beneficial effect of 
aspirin in reducing the incidence of preterm-PE in subgroups defined according to 
maternal age, body mass index, racial origin, method of conception, smoking, family 
history of PE, obstetrical history, and history of pre-existing medical conditions, 
except for chronic hypertension; in chronic hypertension prophylactic use of aspirin 
may not be useful in the prevention of preterm-PE.31 Meta-analyses of trials on the 
use of aspirin in women at high-risk for PE have reported that first, use of aspirin at a 
daily dose of <100 mg or onset at >16 weeks’ gestation did not prevent PE, second, 
aspirin at ≥ 100 mg / day started at <16 weeks reduced the risk of preterm-PE by 
67% but has no significant effect on the incidence of term-PE, and third, aspirin at ≥ 
100 mg / day started at >16 weeks may increase the risk of placental abruption and 
antepartum hemorrhage.32,33  
 
Conclusion 
The competing risks model provides an effective and reproducible method for first-
trimester prediction of preterm-PE, provided the various components of screening are 
carried out by appropriately trained and audited practitioners. Early prediction of 
preterm-PE is beneficial because treatment of the high-risk group with aspirin at a 
daily dose of ≥ 100 mg is highly effective in the prevention of the disease. 
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Table 1. Maternal and pregnancy characteristics in the three populations.  
 
IQR = interquartile range; SLE = systemic lupus erythematosus; APS = antiphospholipid syndrome; 
Comparisons between outcome groups were by chi-square or Fisher exact test for categorical 
variables and Mann Whitney-U test for continuous variables; * significance value p<0.05 in comparison 
of SQS and SPREE with the training set; + significance value p<0.05 in comparison of SQS and 
SPREE. 
 
  
Variables Training set (n=35,948) 
SQC 
(n=8,775) 
SPREE 
(n=16,451) 
Maternal age in years, median (IQR) 31.3 (26.8, 35.0) 31.5 (27.3, 35.0)* 31.5 (27.4, 35.1)* 
Maternal weight in kg, median (IQR) 66.7 (59.0, 77.2) 66.5 (59.0, 77.0)⁺ 67.0 (59.2, 78.0)* 
Maternal height in cm, median (IQR) 164.5 (160.0, 169.0) 164.5 (160.0, 169.0)⁺ 165.0 (160.0, 169.0)* 
Body mass index in kg/m2, median (IQR) 24.5 (22.0, 28.4) 24.5 (21.9, 28.4)⁺ 24.7 (22.0, 28.7)* 
Gestational age in weeks, median (IQR) 12.7 (12.3, 13.1) 12.7 (12.3, 13.1)*⁺ 12.9 (12.4, 13.3)* 
Racial origin  *⁺ * 
  White, n (%) 25,879 (71.99) 6,883 (78.44) 11,922 (72.47) 
  Black, n (%) 6,681 (18.59) 1,090 (12.42) 2,337 (14.21) 
  South Asian, n (%) 1,623 ( 4.51) 462 ( 5.26) 1,361 ( 8.27) 
  East Asian, n (%) 846 ( 2.35) 154 ( 1.75) 407 ( 2.47) 
  Mixed, n (%) 919 ( 2.56) 186 ( 2.12) 424 ( 2.58) 
Conception  *⁺ * 
  Natural 34,743 (96.65) 8,483 (96.67) 15,765 (95.83) 
  Assisted by use of ovulation drugs 349 ( 0.97) 64 ( 0.73) 125 ( 0.76) 
  In vitro fertilization 856 ( 2.38) 227 ( 2.59) 561 ( 3.41) 
Medical history    
  Chronic hypertension 561 ( 1.56) 100 ( 1.14)⁺ 137 ( 0.83)* 
  Diabetes mellitus type 1 137 ( 0.38) 31 ( 0.35)⁺ 46 ( 0.28)* 
  Diabetes mellitus type 2 188 ( 0.52) 37 ( 0.42)⁺ 71 ( 0.43)* 
  SLE/APS 53 ( 0.15) 19 ( 0.22) 39 ( 0.24)* 
Cigarette smokers, n (%) 3,263 ( 9.08) 732 ( 8.34)⁺ 1,105 ( 6.72)* 
Family history of preeclampsia, (n, %) 1,518 ( 4.22) 339 ( 3.86)* 535 ( 3.25)* 
Parity  *⁺ * 
  Nulliparous, n (%) 17,361 (48.29) 4,127 (47.03) 7,587 (46.12) 
  Parous with no previous PE, n (%) 17,311 (48.16) 4,459 (50.81) 8,483 (51.57) 
  Parous with previous PE, n (%) 1,276 ( 3.55) 189 ( 2.15) 381 ( 2.32) 
Preeclampsia    
  Total, n (%) 1,058 ( 2.94) 239 ( 2.72) 439 ( 2.67) 
  Delivery <37 weeks, n (%) 292 ( 0.81) 59 ( 0.67) 135 ( 0.82) 
  Delivery <34 weeks, n (%) 128 (0.36) 27 (0.31) 58 (0.35) 
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Table 2. Performance of screening, with 95% confidence interval, for early-PE, 
preterm-PE and all-PE by the triple test in the three datasets. 
 
  
Method of 
screening 
Discrimination Calibration 
AUROC curve DR for 10% SPR Slope Intercept 
Early-PE 
    
Training set 0.95 (0.93, 0.97) 87 (80, 92) 0.92 (0.84, 1.01) 0.05 (-0.14, 0.23) 
SQS 0.97 (0.95, 0.99) 93 (76, 99) 0.98 (0.80, 1.17) 0.05 (-0.38, 0.48) 
SPREE 0.96 (0.93, 0.98) 90 (78, 96) 0.92 (0.79, 1.04) 0.45 (0.16, 0.73) 
Preterm-PE 
    
Training set 0.91 (0.89, 0.93) 75 (70, 80) 0.95 (0.89, 1.02) -0.19 (-0.32, -0.07) 
SQS 0.93 (0.89, 0.96) 75 (62, 85) 1.00 (0.85, 1.15) -0.19 (-0.47, 0.09) 
SPREE 0.93 (0.92, 0.95) 83 (76, 89) 1.05 (0.95, 1.15) 0.17 (-0.01, 0.35) 
All-PE 
    
Training set 0.83 (0.81, 0.84) 52 (49, 55) 1.07 (1.02, 1.12) -0.57 (-0.64, -0.50) 
SQS 0.82 (0.80, 0.85) 49 (43, 56) 1.06 (0.94, 1.17) -0.44 (-0.58, -0.29) 
SPREE 0.85 (0.83, 0.87) 53 (49, 58) 1.17 (1.08, 1.26) -0.41 (-0.52, -0.31) 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 25
Figure 1. Receiver operating characteristic plots of screening for early-PE, preterm-
PE and all-PE by the triple test in the training set (green line), SQS (blue line), 
SPREE (red line) and the combination of the three datasets (grey line). 
 
Figure 2. Calibration plots for screening using the competing risk model for prediction 
of preterm-PE by the triple test in the three datasets. The diagonal gray line is the line 
of perfect agreement. The overall mean risk is shown by the vertical interrupted line 
and the overall incidence by the horizontal interrupted line. The histograms show the 
distribution of risks in pregnancies with preterm-PE (red) and those without preterm-
PE (grey).  
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Figure S1. Receiver operating characteristic plots of screening for early-PE in the 
three datasets and their combination by maternal factors (left) and the triple test 
(right). 
 
Training set green line; SPREE, red line; SQS blue line; combination of the three 
datasets, grey line. 
 
Figure S2. Receiver operating characteristic plots of screening for preterm-PE in the 
three datasets and their combination by maternal factors (left) and the triple test 
(right). 
 
Training set green line; SPREE, red line; SQS blue line; combination of the three 
datasets, grey line. 
 
 
Figure S3. Receiver operating characteristic plots of screening for all-PE in the three 
datasets and their combination by maternal factors (left) and the triple test (right). 
 
Training set green line; SPREE, red line; SQS blue line; combination of the three 
datasets, grey line. 
 
Figure S4. Calibration plots for screening using the competing risk model for 
prediction of early-PE by the triple test in the three datasets. The diagonal gray line is 
the line of perfect agreement. The overall mean risk is shown by the vertical 
interrupted line and the overall incidence by the horizontal interrupted line. The 
histograms show the distribution of risks in pregnancies with preterm-PE (red) and 
those without preterm-PE (grey). 
 
Figure S5. Calibration plots for screening using the competing risk model for 
prediction of all-PE by the triple test in the three datasets. The diagonal gray line is 
the line of perfect agreement. The overall mean risk is shown by the vertical 
interrupted line and the overall incidence by the horizontal interrupted line. The 
histograms show the distribution of risks in pregnancies with preterm-PE (red) and 
those without preterm-PE (grey). 
 
Figure S6. Calibration plots for screening using the competing risk model for 
prediction of all-PE by the triple test in the three datasets. The diagonal gray line is 
the line of perfect agreement. The overall mean risk is shown by the vertical 
interrupted line and the overall incidence by the horizontal interrupted line. The 
histograms show the distribution of risks in pregnancies with all-PE (red) and those 
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without PE (grey). The incidence counts were adjusted for the effect of censoring by 
multiplying the estimated incidence by the number of observations in each bin.  
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